Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Oncology, Inc.

Hiroki Umehara

Hitoshi Ban

Naoaki Shimada

Seiji Kamioka

Wataru Hirose

Makoto Matsuoka

Kento Hayashi

David J Bearss

Steven L Warner

Adam Siddiqui-Jain

Jason Marc Foulks

Paul Flynn

Akihito Nonoyama

Akihito Kiguchiya

Nozomi Tomimatsu

Ken Fujimura

The present disclosure provides a compound that exerts an anticancer action based on CHK1 inhibition. The present disclosure was completed by finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof exhibits an excellent antitumor action by having a potent inhibitory action against CHK1: wherein R, R, L, V, W, and Q are as defined herein, X, Y, and Z each independently represent CRor a nitrogen atom, wherein X, Y, and Z are not simultaneously CR, and Ris as defined herein.

5-heteroaryl-1H-pyrazol-3-amine derivative

Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.

AXL kinase inhibitors and use of the same

Growing community of inventors

Osaka, Japan

Hiroki Umehara